Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

MicroRNAs Distinguish Burkitt Lymphoma from the Molecular Subsets of Diffuse Large B Cell Lymphoma.

Cassandra L. Jacobs, Anand S. Lagoo, Raj C Dash, Adekunle Raji, Andrew M Evens, Jane N. Winter, Leo I. Gordon, Brad S Kahl, Magdalena Czader, Gopesh Srivastava, Karen P. Mann, Javed Gill, David Rizzieri, Sandeep Dave

Blood (2008) 112 (11): 3353.

https://doi.org/10.1182/blood.V112.11.3353.3353

Published: 2008

Journal Articles

Alemtuzumab and Rituximab Combination Therapy for Patients with Untreated CLL – a Phase II Trial.

Olga Frankfurt, Elizabeth Hamilton, Sara Duffey, Simbi Acharya, Adekunle Raji, Shuo Ma, Loann Peterson, Charles Goolsby, Steven T. Rosen

Blood (2008) 112 (11): 2098.

https://doi.org/10.1182/blood.V112.11.2098.2098

Published: 2008

Journal Articles

Expression of Hypoxia-Inducible Factor (HIF) Is An Independent Favorable Prognostic Factor in Diffuse Large B-Cell Lymphoma (DLBCL) Treated with R-CHOP

Andrew M. Evens, DO, MS, Laurie H. Sehn, MD, MPH, Pedro Farinha, MD, Paul T Schumacker, PhD, Adekunle Raji, MS, Yi Lu, MD, Beverly P. Nelson, MD, Randy D. Gascoyne, MD, Leo I. Gordon, MD

Blood (2008) 112 (11): 479.

https://doi.org/10.1182/blood.V112.11.479.479

Published: 2008

Journal Articles

Hypoxia-Inducible Factor-Alpha (HIF-α) Activation in Non-Hodgkin’s Lymphoma (NHL): Relationship to the Thioredoxin Family and Correlation with Survival by Tissue Microarray (TMA).

Andrew M. Evens, DO, MS, Paul T. Schumacker, PhD, Irene B. Helenowski, MS, Amar Singh, PhD, Danijela Dokic, MD, Anjeni Keswani, MD, Elizabeth Kordeluk, BS, Adekunle Raji, MS, Jane N. Winter, MD, Borko D. Jovanovic, PhD, Arne Holmgren, MD, PhD, Beverly P. Nelson, MD, Leo I. Gordon, MD

Blood (2007) 110 (11): 3587.

https://doi.org/10.1182/blood.V110.11.3587.3587

Published: 2007

Journal Articles

A Phase II Trial of Alemtizimab and Rituximab in Patients with Previously Untreated CLL.

Olga Frankfurt, MD, Elizabeth Hamilton, APN, Simbi Acharya, MS, Sara Duffey, Adekunle Raji, Steven T. Rosen, MD

Blood (2007) 110 (11): 2056.

https://doi.org/10.1182/blood.V110.11.2056.2056

Published: 2007

NARROW

MicroRNAs Distinguish Burkitt Lymphoma from the Molecular Subsets of Diffuse Large B Cell Lymphoma.

Alemtuzumab and Rituximab Combination Therapy for Patients with Untreated CLL – a Phase II Trial.

Expression of Hypoxia-Inducible Factor (HIF) Is An Independent Favorable Prognostic Factor in Diffuse Large B-Cell Lymphoma (DLBCL) Treated with R-CHOP

Hypoxia-Inducible Factor-Alpha (HIF-α) Activation in Non-Hodgkin’s Lymphoma (NHL): Relationship to the Thioredoxin Family and Correlation with Survival by Tissue Microarray (TMA).

A Phase II Trial of Alemtizimab and Rituximab in Patients with Previously Untreated CLL.

Email alerts

ASH Publications

American Society of Hematology

MicroRNAs Distinguish Burkitt Lymphoma from the Molecular Subsets of Diffuse Large B Cell Lymphoma.

Alemtuzumab and Rituximab Combination Therapy for Patients with Untreated CLL – a Phase II Trial.

Expression of Hypoxia-Inducible Factor (HIF) Is An Independent Favorable Prognostic Factor in Diffuse Large B-Cell Lymphoma (DLBCL) Treated with R-CHOP

Hypoxia-Inducible Factor-Alpha (HIF-α) Activation in Non-Hodgkin’s Lymphoma (NHL): Relationship to the Thioredoxin Family and Correlation with Survival by Tissue Microarray (TMA).

A Phase II Trial of Alemtizimab and Rituximab in Patients with Previously Untreated CLL.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only